CLDI Stock Forecast: Calidi Biotherapeutics, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 20 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Calidi Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (76): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (2): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CLDI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CLDI, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 June 2024 | Ladenburg Thalmann | Initiates | Buy | — |
| 15 May 2024 | Baird | Maintains | Outperform | — |
| 21 Mar 2024 | Baird | Maintains | Outperform | — |
| 21 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 22 Nov 2023 | HC Wainwright & Co. | Initiates | Buy | — |
| 9 Oct 2023 | Baird | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
CLDI appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CLDI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.8×
- EV / EBITDA
- —
Cheaper than 76% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −361.8%
- Return on assets
- −109.6%
- Dividend yield
- —
Higher than 4% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Calidi Biotherapeutics, Inc. has a market value of $1.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$17.5M.
Free cash flow in the twelve months to 30 June 2026: −$17.8M.
Calidi Biotherapeutics, Inc. employs 29 people.
Data provided by Twelve Data
CLDI and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CLDI’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Calidi Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CLDI
How does Ticker Nerd's model rank CLDI?
As at 21 Nov 2026, Calidi Biotherapeutics, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (76 of 100).
What is the CLDI stock forecast for 2030?
No analyst covering Calidi Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLDI are extrapolating price history, which says nothing about the business.
What does Calidi Biotherapeutics, Inc. do?
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies that deliver genetic medicines to sites of disease. The company’s current programs center on stem cell-based and oncolytic virus platforms designed to transport therapeutic payloads directly into tumors while helping protect them from premature immune clearance.
About Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies that deliver genetic medicines to sites of disease. The company’s current programs center on stem cell-based and oncolytic virus platforms designed to transport therapeutic payloads directly into tumors while helping protect them from premature immune clearance. Its portfolio includes product candidates for cancers such as high-grade glioma and solid tumors, reflecting a focus on oncology and precision delivery methods. Calidi Biotherapeutics also works across systemic and localized treatment approaches, using proprietary cell-based technologies to support tumor targeting, immune activation, and controlled payload delivery. Headquartered in San Diego, California, Calidi Biotherapeutics plays a role in the broader biopharmaceutical market as a developer of advanced immuno-oncology and gene therapy solutions.
CEO Dr. Eric E. Poma Ph.D. · 29 employees · United States · https://www.calidibio.com